Realtime | Geld | Brief | Zeit |
---|---|---|---|
38,605 | 38,620 | 14:28 | |
38,605 | 38,620 | 14:28 |
Stück | Geld | Kurs | Brief | Stück |
---|---|---|---|---|
38,720 | 226 | |||
38,715 | 419 | |||
38,710 | 240 | |||
38,705 | 440 | |||
38,700 | 713 | |||
38,695 | 665 | |||
38,690 | 608 | |||
38,685 | 665 | |||
38,680 | 580 | |||
38,675 | 200 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/qia.htm [/URL] | ||||
200 | 38,660 | |||
411 | 38,655 | |||
607 | 38,650 | |||
598 | 38,645 | |||
717 | 38,640 | |||
665 | 38,635 | |||
329 | 38,630 | |||
410 | 38,625 | |||
662 | 38,620 | |||
265 | 38,615 | |||
Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
4.864 | 0,978 | 4.756 |
Uhrzeit | Aktienkurs | Stück |
---|---|---|
14:13:45 | 38,660 | 13 |
14:13:27 | 38,660 | 7 |
14:13:27 | 38,670 | 50 |
14:13:07 | 38,690 | 25 |
14:11:29 | 38,695 | 30 |
14:11:03 | 38,695 | 58 |
14:07:45 | 38,690 | 3 |
14:02:23 | 38,655 | 92 |
14:01:19 | 38,665 | 2 |
13:58:31 | 38,695 | 181 |
13:58:27 | 38,705 | 262 |
13:58:16 | 38,700 | 23 |
13:58:16 | 38,695 | 177 |
13:58:14 | 38,700 | 439 |
13:58:14 | 38,700 | 23 |
13:57:42 | 38,700 | 55 |
13:57:10 | 38,730 | 52 |
13:57:04 | 38,720 | 78 |
13:55:03 | 38,720 | 179 |
13:55:01 | 38,720 | 173 |
Tagesumsatz Xetra | +0,395 +1,03 % | 74.680 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
13:50 | QIAGEN stärkt Genomik durch Übernahme von Genoox | 4 | IT BOLTWISE | ||
13:35 | QIAGEN Stock Gains Following the Acquisition of Genoox | 3 | Zacks | ||
10:26 | Qiagen: Fortschritte in der molekularen Diagnostik und Kooperation mit Bayer | 22 | IT BOLTWISE | ||
08:38 | Qiagen: KI-Übernahme - die Hintergründe! | 262 | Der Aktionär | Das DAX-Unternehmen Qiagen verstärkt sich im Bereich der Künstlichen Intelligenz (KI). Mit der Übernahme der KI-gestützten Software von der israelischen Genoox will der Diagnostik-Spezialist mit Hauptsitz... ► Artikel lesen | |
QIAGEN Aktie jetzt für 0€ handeln | |||||
07:13 | Qiagen buys Israeli AI software co Genoox | 3 | Globes |
Zeit | Aktuelle Nachrichten | Medien | ||
---|---|---|---|---|
13:54 | Anavex Life Sciences Corp. Q2 Loss Beats Estimates | AFX News | WASHINGTON (dpa-AFX) - Anavex Life Sciences Corp. (AVXL) released Loss for second quarter that beat the Street estimates.The company's earnings came in at -$11.20 million, or -$0.13 per share.... ► Artikel lesen | |
14:06 | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | GlobeNewswire (Europe) | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
14:06 | Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights | GlobeNewswire (Europe) | Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American... ► Artikel lesen | |
13:48 | Polyrizon Ltd.: Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment | GlobeNewswire (Europe) | Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal... ► Artikel lesen | |
13:36 | Cytokinetics, Incorporated: Cytokinetics Announces Positive Topline Results From MAPLE-HCM | GlobeNewswire (Europe) | Trial Demonstrates Superiority of Aficamten to Standard of Care Beta Blocker in Improving Peak Exercise Capacity in Patients with Obstructive Hypertrophic Cardiomyopathy SOUTH SAN FRANCISCO, Calif.... ► Artikel lesen |